F M Vasques Godinho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
F M Vasques Godinho has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ana Filipa Mourão
Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Portugal
1 shared publication - Anabela Barcelos
Rheumatology Department, Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal
1 shared publication - Dário Ligeiro
Lisbon Centre for Blood and Transplantation, Instituto Português do Sangue e Transplantação, Lisbon, Portugal
1 shared publication - Fernando Manuel Pimentel-Santos
INOVA4 Health, NOVA Medical School, Lisbon, Portugal
1 shared publication - Gethin P. Thomas
The University of Queensland Diamantina Institute, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.
1 shared publication - Helena Santos
EpiDoc Unit/Comprehensive Health Research Center -Nova Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.
1 shared publication
Latest Publications
- Open Access
- 7 April 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (2) , R57
Whole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects
Introduction: A number of genetic-association studies have identified genes contributing to ankylosing spondylitis (AS) susceptibility but such approaches provide little information as to the gene activity changes occurring during the disease process. Transcriptional profiling generates a 'snapshot' of the sampled cells' activity and thus can provide insights into the molecular processes driving the disease process. We undertook a whole-genome microarray approach to identify candidate genes associated with AS and validated these gene-expression changes in a larger sample cohort.Methods: A total of 18 active AS patients, classified according to the New York criteria, and 18 gender- and age-matched controls were profiled using Illumina HT-12 whole-genome expression BeadChips which carry cDNAs for 48,000 genes and transcripts. Class comparison analysis identified a number of differentially expressed candidate genes. These candidate genes were then validated in a larger cohort using qPCR-based TaqMan low density arrays (TLDAs).Results: A total of 239 probes corresponding to 221 genes were identified as being significantly different between patients and controls with aP-value SPOCK2(osteonectin) andEP300, which modulate cartilage and bone metabolism.Conclusions: We have validated a gene expression signature for AS from whole blood and identified strong candidate genes that may play roles in both the inflammatory and joint destruction aspects of the disease.
- 7 April 2011
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 13 (2) , R57
Open AccessWhole blood transcriptional profiling in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and tissue-destructive disease aspects
Introduction: A number of genetic-association studies have identified genes contributing to ankylosing spondylitis (AS) susceptibility but such approaches provide little information as to the gene activity changes occurring during the disease process. Transcriptional profiling generates a 'snapshot' of the sampled cells' activity and thus can provide insights into the molecular processes driving the disease process. We undertook a whole-genome microarray approach to identify candidate genes associated with AS and validated these gene-expression changes in a larger sample cohort.Methods: A total of 18 active AS patients, classified according to the New York criteria, and 18 gender- and age-matched controls were profiled using Illumina HT-12 whole-genome expression BeadChips which carry cDNAs for 48,000 genes and transcripts. Class comparison analysis identified a number of differentially expressed candidate genes. These candidate genes were then validated in a larger cohort using qPCR-based TaqMan low density arrays (TLDAs).Results: A total of 239 probes corresponding to 221 genes were identified as being significantly different between patients and controls with aP-value SPOCK2(osteonectin) andEP300, which modulate cartilage and bone metabolism.Conclusions: We have validated a gene expression signature for AS from whole blood and identified strong candidate genes that may play roles in both the inflammatory and joint destruction aspects of the disease.
- Open Access
- 1 April 2005
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (4) , 647-648
Refractory adult onset Still's disease successfully treated with anakinra
We report a favourable response to anakinra in a patient unresponsive to several disease modifying antirheumatic drugs (DMARDs) and TNFα blockers, requiring chronic high doses of steroids. The patient is a 32 year old woman diagnosed at the age 18 with AOSD, defined by the criteria of Yamaguchi et al.10 She was treated with NSAIDs, systemic steroids, and several DMARDs (MTX, sulfasalazine, and ciclosporin A) over a period of 10 years, but she had sustained disease with frequent flares requiring high doses of steroids (up to 1 mg/kg/day).
- 1 April 2005
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (4) , 647-648
Open AccessRefractory adult onset Still's disease successfully treated with anakinra
We report a favourable response to anakinra in a patient unresponsive to several disease modifying antirheumatic drugs (DMARDs) and TNFα blockers, requiring chronic high doses of steroids. The patient is a 32 year old woman diagnosed at the age 18 with AOSD, defined by the criteria of Yamaguchi et al.10 She was treated with NSAIDs, systemic steroids, and several DMARDs (MTX, sulfasalazine, and ciclosporin A) over a period of 10 years, but she had sustained disease with frequent flares requiring high doses of steroids (up to 1 mg/kg/day).